Business Description
CalciMedica Inc
NAICS : 541714
SIC : 2834
ISIN : US38942Q2021
Share Class Description:
CALC: Ordinary SharesTotal Employee Number:
15Description
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.02 | |||||
Equity-to-Asset | 0.28 | |||||
Debt-to-Equity | 1.67 | |||||
Debt-to-EBITDA | -0.46 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 73 | |||||
3-Year EPS without NRI Growth Rate | 79.8 | |||||
3-Year FCF Growth Rate | 78.7 | |||||
3-Year Book Growth Rate | 78.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 34.43 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 39.7 | |||||
9-Day RSI | 35.78 | |||||
14-Day RSI | 36.24 | |||||
3-1 Month Momentum % | -29.25 | |||||
6-1 Month Momentum % | -2.37 | |||||
12-1 Month Momentum % | -5.59 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.58 | |||||
Quick Ratio | 5.58 | |||||
Cash Ratio | 5.33 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -115.1 | |||||
Shareholder Yield % | -115.04 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -2947.54 | |||||
ROA % | -140.3 | |||||
ROIC % | -2404.56 | |||||
3-Year ROIIC % | 1760.95 | |||||
ROC (Joel Greenblatt) % | -35238.52 | |||||
ROCE % | -178.23 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 2.2 | |||||
Price-to-Tangible-Book | 2.2 | |||||
EV-to-EBIT | -0.21 | |||||
EV-to-Forward-EBIT | -0.23 | |||||
EV-to-EBITDA | -0.21 | |||||
EV-to-Forward-EBITDA | -0.23 | |||||
EV-to-Forward-Revenue | 4.49 | |||||
EV-to-FCF | -0.21 | |||||
| Price-to-Net-Current-Asset-Value | 2.22 | |||||
| Price-to-Net-Cash | 2.64 | |||||
Earnings Yield (Greenblatt) % | -476.19 | |||||
FCF Yield % | -141.39 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CALC
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
CalciMedica Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -6.8 | ||
| Beta | 1.5032 | ||
| 3-Year Sharpe Ratio | 0.45 | ||
| 3-Year Sortino Ratio | 1.04 | ||
| Volatility % | 147.62 | ||
| 14-Day RSI | 36.24 | ||
| 14-Day ATR ($) | 0.300529 | ||
| 20-Day SMA ($) | 2.619325 | ||
| 12-1 Month Momentum % | -5.59 | ||
| 52-Week Range ($) | 1.91 - 36 | ||
| Shares Outstanding (Mil) | 6.83 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
CalciMedica Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
CalciMedica Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2027-03-03 | In 173 days | ||
| Fourth quarter earnings results for 2027 | 2027-03-03 | In 173 days | ||
| Third quarter earnings results for 2026 | 2026-11-12 | In 62 days | ||
| 0.2:1 Stock Split | 2026-08-31 | 2.32 (-0.36%) | ||
| General meeting for 2026 | 2026-08-19 09:00 | 3.19 (-4.16%) | ||
| Second quarter earnings results for 2026 | 2026-08-11 | 3.30 (-1.64%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 2.96 (-5.70%) | ||
| Annual report for 2025 | 2026-03-03 | 2.54 (-1.46%) | ||
| Fourth quarter earnings results for 2026 | 2026-03-03 | 2.54 (-1.46%) | ||
| Third quarter earnings results for 2025 | 2025-11-12 | 3.21 (+4.90%) |
Show
Entries
CalciMedica Inc Frequently Asked Questions
What is CalciMedica Inc(CALC)'s stock price today?
The current price of CALC is $1.98. The 52 week high of CALC is $36.00 and 52 week low is $1.91.
When is next earnings date of CalciMedica Inc(CALC)?
The next earnings date of CalciMedica Inc(CALC) is 2026-11-12 Est..
Does CalciMedica Inc(CALC) pay dividends? If so, how much?
CalciMedica Inc(CALC) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers